Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Journal of Nuclear Medicine · 2025-01 · 66 (1) · 61-66
DOI: 10.2967/jnumed.124.268807 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.11.2024. Verfasst von Mike Wenzel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany; mike.wenzel@unimedizin-ffm.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radiopharmaceuticals, Taxoids. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
177Lu-vipivotide tetraxetan prostate-specific membrane antigen (177Lu-PSMA) therapy is under current scientific investigation and aims to become established in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant.
Methods
We relied on the FRAMCAP database and compared cabazitaxel versus 177Lu-PSMA therapy in mCRPC patients regarding progression-free survival (PFS) and overall survival (OS). Sensitivity analyses addressed second- to fourth-line mCRPC treatment to approximate current phase III patient selection criteria.
Results
Of 373 patients, 14% received cabazitaxel, 65% received 177Lu-PSMA, and 21% received both. Patients undergoing 177Lu-PSMA therapy were significantly older than cabazitaxel patients (median, 72 y vs. 66 y; P < 0.01), and a higher proportion had an Eastern Cooperative Oncology Group score of 2 or more (12% vs. 5.0%, P = 0.1). Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for 177Lu-PSMA versus cabazitaxel. In outcome analyses, significant superior median PFS was observed for 177Lu-PSMA versus cabazitaxel (13.4 mo vs. 7.1 mo, P < 0.001), even after multivariable adjustment (hazard ratio, 0.38; P < 0.001). Regarding OS, rates also significantly differed, with median OS of 14.7 mo versus 16.5 mo versus 29.6 mo for cabazitaxel versus 177Lu-PSMA versus both treatments (P < 0.01). In sensitivity analyses of second- to fourth-line mCRPC treatment, PFS rates and median OS rates for cabazitaxel versus 177Lu-PSMA versus both therapies qualitatively remained the same as for the entire cohort.
Conclusion
In a real-world setting, 177Lu-PSMA provides significantly better PFS and qualitatively better OS rates than does cabazitaxel chemotherapy and should therefore be considered a valuable treatment option for advanced mCRPC patients according to the European Medicines Agency approval.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany; mike.wenzel@unimedizin-ffm.de.
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
- Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and.
- Hematology/Oncology, Department of Medicine, University Hospital Frankfurt, Goethe University, Frankfurt Am Main, Germany.
Zitieren
APA
Wenzel, M., Koll, F., Hoeh, B., Humke, C., Siech, C., Mader, N., Sabet, A., Groener, D., Steuber, T., Graefen, M., Maurer, T., Brandts, C., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 66(1), 61-66. https://doi.org/10.2967/jnumed.124.268807
Vancouver
Wenzel M, Koll F, Hoeh B, Humke C, Siech C, Mader N, et al. Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2025;66(1):61-66. doi:10.2967/jnumed.124.268807
BibTeX
@article{Wenzel2025,
author = {Wenzel, Mike and Koll, Florestan and Hoeh, Benedikt and Humke, Clara and Siech, Carolin and Mader, Nicolai and Sabet, Amir and Groener, Daniel and Steuber, Thomas and Graefen, Markus and Maurer, Tobias and Brandts, Christian and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
title = {Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2025},
volume = {66},
number = {1},
pages = {61--66},
doi = {10.2967/jnumed.124.268807}
}
EUVIMED